• SUKHPAL SINGH Department of Biotechnology, University Institute of Engineering and Technology, Panjab University, Chandigarh,
  • AMITA MAHAJAN I. K. Gujral Punjab Technical University, Jalandhar,
  • JASPREET KAUR Department of Biotechnology, University Institute of Engineering and Technology, Panjab University, Chandigarh,


Objective: This study was done to explore the correlation if any, between obesity markers adiponectin, leptin, and protein oxidative stress (OS) status in obese with and without type 2 diabetic mellitus (T2DM) patients.

Methods: In the present study, 30 healthy subjects, 30 obese non-diabetics, and 30 obese T2DM patients were enrolled. Protein OS parameters such as advanced oxidation of protein products (AOPPs) and protein carbonyl (PC) were estimated. Serum leptin, adiponectin, and insulin levels were measured by ELISA.

Results: The AOPP, PC, leptin, leptin adiponectin ratio (LAR), insulin, and homeostasis model assessment of insulin resistance (HOMA-IR) levels were significantly higher in obese non-diabetic and obese T2DM as compared to healthy control (p<0.001). However, serum adiponectin levels were significantly lower in obese non-diabetic and obese T2DM as compared to control (p<0.001). HOMA-IR and LAR both the index of IR were increased in obese non-diabetic and obese T2DM. Positive correlations were observed for AOPP with body mass index, PC in obese non-diabetic and with fasting blood glucose, postprandial blood glucose, HOMA-IR, and PC in obese T2DM. A negative correlation was found between PC and adiponectin in obese non-diabetic and obese T2DM. A significant inverse correlation was obtained between leptin and adiponectin in obese T2DM only.

Conclusion: The present study suggested that increased protein OS, hyperinsulinemia, and hyperleptinemia may lead to hypoadiponectinemia in obese with and without T2DM. Moreover, determination of protein oxidation markers can be useful for monitoring the dysregulation of adipokines and glucose metabolism in obesity and T2DM.

Keywords: Obesity,, Type 2 diabetes,, Adiponectin,, Leptin,, Protein carbonyl.


1. Matsuda M, Shimomura I. Increased oxidative stress in obesity: Implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. Obes Res Clin Pract 2013;7:e330-41.2. Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 2006;83:461S-465S.
3. Nakanishi S, Yamane K, Kamei N, Nojima H, Okubo M, Kohno N, et al. A protective effect of adiponectin against oxidative stress in Japanese Americans: The association between adiponectin or leptin and urinary isoprostane. Metabolism 2005;54:194-9.
4. Blüher M, Mantzoros CS. From leptin to other adipokines in health and disease: Facts and expectations at the beginning of the 21st century. Metabolism 2015;64:131-45.
5. Yadav A, Kataria MA, Saini V, Yadav A. Role of leptin and adiponectin in insulin resistance. Clin Chim Acta 2013;417:80-4.
6. Yamauchi T, Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab 2013;17:185 96.
7. Aleidi S, Issa A, Bustanji H, Khalil M, Bustanji Y. Adiponectin serum levels correlate with insulin resistance in Type 2 diabetic patients. Saudi Pharm J 2015;23:250-6.
8. Shibata R, Murohara T, Ouchi N. Protective role of adiponectin in cardiovascular disease. Curr Med Chem 2012;19:5459-66.
9. Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab 2016;23:770-84.
10. Saad EA, Habib SA, Refai WA, Elfayoumy AA. Malondialdehyde, adiponectin, nitric oxide, C reactive protein, tumor necrosis factor-alpha and insulin resistance relationships and inter-relationships in Type 2 diabetes early stage is metformin alone adequate in this stage. Int J Pharm Pharm Sci 2017;9:176-81.
11. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-6.
12. Iikuni N, Lam QL, Lu L, Matarese G, La Cava A. Leptin and inflammation. Curr Immunol Rev 2008;4:70-9.
13. Al-Hamodi Z, Al-Habori M, Al-Meeri A, Saif-Ali R. Association of adipokines, leptin/adiponectin ratio and C-reactive protein with obesity and Type 2 diabetes mellitus. Diabetol Metab Syndr 2014;6:99.
14. Farooqi IS, O’Rahilly S. Leptin: A pivotal regulator of human energy homeostasis. Am J Clin Nutr 2009;89:980S-984S.
15. Chen VC, Chen CH, Chiu YH, Lin TY, Li FC, Lu ML, et al. Leptin/adiponectin ratio as a potential biomarker for metabolic syndrome in patients with schizophrenia. Psychoneuroendocrinology 2018;92:34 40.
16. Hamed EA, Zakary MM, Ahmed NS, Gamal RM. Circulating leptin and insulin in obese patients with and without Type 2 diabetes mellitus: Relation to ghrelin and oxidative stress. Diabetes Res Clin Pract 2011;94:434-41.
17. Fernández-Sánchez A, Madrigal-Santillán E, Bautista M, Esquivel-Soto J, Morales-González A, Esquivel-Chirino C, et al. Inflammation, oxidative stress, and obesity. Int J Mol Sci 2011;12:3117-32.
18. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillère-Blandin C, Nguyen AT, Canteloup S, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998;161:2524-32.
19. Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 2002;162:221-5.
20. Piwowar A, Knapik-Kordecka M, Warwas M. AOPP and its relations with selected markers of oxidative/antioxidative system in Type 2 diabetes mellitus. Diabetes Res Clin Pract 2007;77:188-92.
21. Reznick AZ, Packer L. Oxygen radicals in biological systems Part C. Methods Enzymol 1994;233:357-63.
22. Gelisgen R, Genc H, Kayali R, Oncul M, Benian A, Guralp O, et al. Protein oxidation markers in women with and without gestational diabetes mellitus: A possible relation with paraoxonase activity. Diabetes Res Clin Pract 2011;94:404-9.
23. Atabek ME, Keskin M, Yazici C, Kendirci M, Hatipoglu N, Koklu E, et al. Protein oxidation in obesity and insulin resistance. Eur J Pediatr 2006;165:753-6.
24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
26. Salah A, Ragab M, Mansour W, Taher M. Leptin and adiponectin are valuable serum markers explaining obesity bronchial asthma interrelationship. Egypt J Chest Dis Tuberc 2015;64:529-33.
27. Hong SB, Lee JJ, Kim SH, Suh YJ, Han JY, Kim YS, et al. The effects of adiponectin and inflammatory cytokines on diabetic vascular complications in obese and non-obese patients with Type 2 diabetes mellitus. Diabetes Res Clin Pract 2016;111:58-65.
28. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and Type 2 diabetes. Diabetes Res Clin Pract 2014;105:141-50.
29. Fernández-Real JM, Botas-Cervero P, López-Bermano A, Casamitjana R, Funahashi T, Delgado E, et al. Adiponectin is independently associated with glycosylated haemoglobin. Eur J Endocrinol 2004;150:201-5.
30. Inoue M, Yano M, Yamakado M, Maehata E, Suzuki S. Relationship between the adiponectin-leptin ratio and parameters of insulin resistance in subjects without hyperglycemia. Metabolism 2006;55:1248-54.
31. Ali SH, Al-nuaimi AM, Al-musawi BJ. Serum irisin and leptin levels in obese and non-obese women with polycystic ovary syndrome with reference to glucose homeostasis. Int J Pharm Pharm Sci 2016;8:276 83.
32. Stefanovi? A, Kotur-Stevuljevi? J, Spasi? S, Bogavac-Stanojevi? N, Bujisi? N. The influence of obesity on the oxidative stress status and the concentration of leptin in Type 2 diabetes mellitus patients. Diabetes Res Clin Pract 2008;79:156-63.
33. Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 2002;147:173-80.
34. Satoh N, Naruse M, Usui T, Tagami T, Suganami T, Yamada K, et al. Leptin-to-adiponectin ratio as a potential atherogenic index in obese Type 2 diabetic patients. Diabetes Care 2004;27:2488-90.
35. Kotani K, Sakane N, Saiga K, Kurozawa Y. Leptin: Adiponectin ratio as an atherosclerotic index in patients with Type 2 diabetes: Relationship of the index to carotid intima-media thickness. Diabetologia 2005;48:2684-6.
36. Gupta V, Mishra S, Mishra S, Kumar S, Gupta V. Association of leptin: Adiponectin ratio and metabolic risk markers in postmenopausal women. Immunol Lett 2018;196:63-7.
37. Krzystek-Korpacka M, Patryn E, Boehm D, Berdowska I, Zielinski B, Noczynska A, et al. Advanced oxidation protein products (AOPPs) in juvenile overweight and obesity prior to and following weight reduction. Clin Biochem 2008;41:943-9.
38. Liang M, Wang J, Xie C, Yang Y, Tian JW, Xue YM, et al. Increased plasma advanced oxidation protein products is an early marker of endothelial dysfunction in Type 2 diabetes patients without albuminuria 2. J Diabetes 2014;6:417-26.
39. Koçak H, Oner-Iyido?an Y, Gürdöl F, Oner P, Süzme R, Esin D, et al. Advanced oxidation protein products in obese women: Its relation to insulin resistance and resistin. Clin Exp Med 2007;7:173-8.
40. Li H, Yin Q, Li N, Ouyang Z, Zhong M. Plasma markers of oxidative stress in patients with gestational diabetes mellitus in the second and third trimester. Obstet Gynecol Int 2016;2016:3865454.
41. Pandey KB, Mishra N, Rizvi SI. Protein oxidation biomarkers in plasma of Type 2 diabetic patients. Clin Biochem 2010;43:508-11.
42. Bollineni RC, Fedorova M, Blüher M, Hoffmann R. Carbonylated plasma proteins as potential biomarkers of obesity induced Type 2 diabetes mellitus. J Proteome Res 2014;13:5081-93.
43. Frohnert BI, Sinaiko AR, Serrot FJ, Foncea RE, Moran A, Ikramuddin S, et al. Increased adipose protein carbonylation in human obesity. Obesity (Silver Spring) 2011;19:1735-41.
44. Perkins BA, Rabbani N, Weston A, Ficociello LH, Adaikalakoteswari A, Niewczas M, et al. Serum levels of advanced glycation endproducts and other markers of protein damage in early diabetic nephropathy in Type 1 diabetes. PLoS One 2012;7:e35655.
45. Indulekha K, Surendar J, Anjana RM, Gokulakrishnan K, Balasubramanyam M, Aravindhan V, et al. Circulating levels of high molecular weight (HMW) adiponectin and total adiponectin in relation to fat distribution, oxidative stress and inflammation in asian Indians. Dis Markers 2012;33:185-92.
178 Views | 22 Downloads
How to Cite
Original Article(s)